UK-based medical cannabis cultivator, Glass Pharms, has announced a new supply agreement with Integro Clinic & IPS Pharmacy. The agreement will provide Integro and Medicann clinics, as well as other UK clinics, with a premium range of Glass Pharms branded CBPMs made with domestically grown flower.
The partnership comes after positive patient feedback from earlier this year, when IPS began prescribing Glass Pharms derived CBPMs. This success has led to an expansion in the range, with five new products based on cultivars produced by Glass Pharms now available.
Glass Pharms CEO James Duckenfield expressed his excitement about the agreement, stating, “We are delighted to announce this direct supply agreement following a period of evaluation where IPS has been prescribing products based on Glass Pharms brand with very positive patient feedback.” He also added that they are looking forward to expanding the availability of CBPMs and offering new prescribing options.
Tony Dutta, CEO of IPS Pharma, also shared his enthusiasm for the partnership, saying, “We are pleased to be supporting a UK-based supply chain that gives patients surety over continuity of their prescribing needs.” He highlighted Glass Pharms’ commitment to quality and sustainability, as well as their ability to fulfill patient needs with balanced and CBG flowers.
Glass Pharms has been working to scale their production capacities at their 2.4-hectare facility in Wiltshire, which boasts best-in-class sustainability credentials and a quality-by-design approach to microbial safety in the production of medical cannabis flower. With the UK medical cannabis market showing healthy growth year-on-year, this partnership aims to provide patients with a reliable and affordable source of medical cannabis.
For more information, please contact Mark Heley at info@glasspharms.com.
Glass Pharms: https://glasspharms.com/
IPS Pharma: https://ips-pharma.com/
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.